A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy

Journal of Nuclear Medicine

Volumn 39, Issue 7, 1998, Pages 1223-1229

  Shen, Sui ^a   DeNardo, Gerald L ^b   Jones, Troyce D ^b   Wilder, Richard B ^b   O'Donnell, Robert T ^b   DeNardo, Sally J ^b  

^a Radiodiagnosis and Therapy   (United States)

^b NONE

Author keywords

Marrow cell kinetics; Radiation dosimetry; Radioimmunotherapy; Radionuclide therapy; Thrombocytopenia

Indexed keywords

6 [4 (BROMOACETAMIDO)BENZYL] 1,4,8,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID; COPPER 67; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DOSIMETRY; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TOXICITY TESTING;

ANIMALS; BONE MARROW CELLS; BURKITT LYMPHOMA; CELL CYCLE; COPPER RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, RADIATION; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; THROMBOCYTOPENIA;

EID: 0031816224     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. DeNardo GL, DeNardo SJ, Macey DJ, Shen S, Kroger LA. Overview of radiation myelotoxicity secondary to radioimmunotherapy using I-131-Lym-1 as a model. Cancer 1994;73(suppl):1038-1048.
2. Wilder RB, Fowler JF, DeNardo GL, Shen S, Wessels BW, DeNardo SJ. Use of the linear-quadratic model to compare doses delivered to the bone marrow by fractionated I-131-Lym-1. Antibody Immunoconj Radiopharm 1995;8:227-239.
3. Juweid M, Behr T, Sharkey RM, Dunn R, Rubin AD, Goldenberg DM. Factors affecting the relationship between the red marrow dose and myelotoxicity in patients receiving radioimmunotherapy with I-131-labeled anti-CEA monoclonal antibodies [Abstract]. J Nucl Med 1996;37:43p.
4. Eary JF, Krohn KA, Press OW, Fisher D, Bernstein ID. Radioimmunotherapy treatment planing based on radiation absorbed dose or patient size [Abstract]. J Nucl Med 1996;37:43p.
5. Sgouros G. Divgi CR, Scott AM. Williams J, Larson SM. Hematologic toxicity in radioimmunotherapy: an evaluation of different predictive measures [Abstract]. J. Nucl Med 1996;5:43p.
6. Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J Nucl Med 1996;37:695-698.
7. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990;18:1261-1269.
8. DeNardo GL, Kukis DL, Shen S, et al. Efficacy and toxicity of Cu-67-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). Clin Cancer Res 1997;3:71-79.
9. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515-528.
10. O'Donoghue JA. The impact of tumor cell proliferation in radioimmunotherapy. Cancer 1994;73:974-980.
11. Hendry JH, Lord BI. The analysis of the early and late response to cytotoxic insults in the haemopoietic cell hierarchy. In: Potten CS, Hendry JH, eds. Cytotoxic insult to tissue. Edinburgh: Churchill-Livingstone; 1983:1-66.
12. Testa NG, Hendry JH, Molineux G. Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res 1985;5:101-110.
13. Schofield R. Assessment of cytotoxic injury to bone marrow. Br J Cancer 1986; 53(suppl 7):115-125.
14. Ebbe S. Origin, production and life-span of blood platelets. In: Johnson SA, ed. The circulating platelet. New York: Academic Press; 1971:19-43.
15. Ratajczak MZ, Gewirtz AM. The biology of hematopoietic stem cells. Semin Oncol 1995;22:210-217.
16. Bithell TC. Platelets and megakaryocytes. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's clinical hematology, 9th ed. Philadelphia and London: Lea & Febiger; 1993:511-530.
17. Jones TD, Morris MD, Young RW. A mathematical model for radiation-induced myelopoiesis. Radiat Res 1991;128:258-266.
18. Jones TD, Morris MD, Young RW. Mathematical models of marrow cell kinetics: differential effects of protracted irradiations on stromal and stem cells in mice. Int J Radiat Oncol Biol Phys 1993;26:817-830.
19. Ellett WH, Humes RM. Absorbed fractions for small volumes containing photon-emitting radioactivity. MIRD pamphlet no. 8. New York: Society of Nuclear Medicine; 1971.
20. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. MIRD pamphlet no. 7. New York: Society of Nuclear Medicine; 1971.
21. Hui ED, Fisher DR, Kuhn JA, Williams LE, Nourigat C, Badger CC, Beatty BG, Beatty JD. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer 1994;73(suppl):951-957.
22. Report of the task group on reference man. In: Snyder WS, Cook MJ, Nasset ES, et al. International Commission on Radiological Protection, no. 23. Oxford: Pergamon Press; 1974:38.
23. Watt DE. Track structure data for ionizing radiation in liquid water. In: University report BIOPHYS 10. St. Andrews, Scotland: University of St. Andrews; 1989.
24. Muthuswamy MS, Roberson PL, Buchsbaum. A mouse bone marrow dosimetry model [Abstract]. Med Phys 1996;23:1090.
25. Goddu SM, Howell RW, Rao DV. Biological dosimetry of bone marrow for incorporated Y-90 [Abstract]. J Nucl Med 1997;38:118p.
26. Siegel JA, Wessels BW, Waston EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antib Immunoconjug Radiopharm 1990;3:213-233.
27. Shen S, DeNardo GL, DeNardo SJ, et al. Dosimetric evaluation for radioimmunotherapy of Cu-64-2IT-BAT-Lym-1 in Cu-67-2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl. Med 1996;37:146-150.